Artículos del autor

Dr. Omar Tupayachi

Member of the Editorial Board of solaci.org

ESC 2025 | HI-PRO: Extended Apixaban for Recurrence Prevention in Provoked DVT/PE

Patients with provoked venous thromboembolism (VTE) usually discontinue anticoagulation after 3 to 6 months. However, in the...

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

The routine use of beta-blockers after acute myocardial infarction (AMI) has been a historical recommendation based on...

ESC 2025 | DOUBLE-CHOICE: Anesthesia Strategies and Self-Expanding Valves in TAVI

TAVI has become the predominant treatment for severe aortic stenosis. The DOUBLE-CHOICE trial analyzed two key aspects:...

ESC 2025 | DIGIT-HF: Digitoxin in Heart Failure with Reduced Ejection Fraction

Heart failure with reduced ejection fraction (HFrEF) continues to represent a clinical challenge despite advances in pharmacological...

Clinical Impact of Peridevice Leak Following Left Atrial Appendage Closure

Left atrial appendage closure (LAAO) has consolidated as a valid strategy for thromboembolic event prevention in patients...

Pulsed-Field Ablation: Proximity to Coronary Vessels and the Unresolved Issue of Induced Vasospasm

Pulsed-field ablation (PFA) has emerged as a promising technique in the treatment of atrial fibrillation, thanks to...

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) remains subject to controversy....

Post TAVR Conduction Disturbances: Same Day Permanent Pacemaker Implantation

TAVR has consolidated as standard of care for aortic stenosis. In recent years, high volume centers have...